MDClone, an innovative healthcare technology company, has recently raised $63 million in Series C funding to fuel global growth. This news has attracted the healthcare industry’s attention and created a buzz in the market.

MDClone is a leading provider of digital health services, powering healthcare quality improvement processes and revolutionising healthcare access through cutting-edge technologies and advanced analytics. MDClone is poised to expand its growth and transform the healthcare landscape with the new resources.

MDClone Raises $63 Million in Series C Funding to Fuel Global Growth

MDClone is an advanced digital health platform that simplifies data collection and enables rapid transformation of healthcare analytics. The platform’s innovative features revolutionises how healthcare professionals make decisions by providing real-time evidence-based insights in a simple, consolidated format. MDClone’s combined data visualisation and machine learning capabilities allow healthcare providers to assess new treatments quickly and accurately diagnose patient conditions faster than ever before.

The MDClone platform is designed to securely integrate medical records across provider organisations so patients can easily receive timely care at the most appropriate place. By leveraging smart technology, such as AI-driven pattern recognition and natural language processing, the platform facilitates predictive analytics that deliver actionable insights for individuals and organisations. Furthermore, MDClone’s intuitive user interface allows clinicians to quickly interpret results without requiring extensive training or additional resources.

In addition to acting as a comprehensive data collection and analysis tool for healthcare professionals, MDClone creates an ecosystem of transparency between patients, providers, payers, regulators and other industry stakeholders. Furthermore, by providing easy access to unified medical record systems compliant with best practices established by government agencies such as the Department of Health & Human Services (HHS), the platform reduces administrative burden while enabling users to comply with all applicable regulations. In summary, MDClone represents a revolutionary advancement in digital health solutions that will improve patient outcomes while ensuring organisational security and compliance with industry standards.

The Impact of MDClone on the Healthcare Industry

MDClone is revolutionising the healthcare industry by providing an innovative patient data and analytics platform. The company has created a single source of information, enabling health practitioners to manage patient care efficiently and with more accuracy than ever before.

In addition to improving data collection, MDClone is creating increased opportunities for preventive health by giving physicians access to actionable insights that can be used to identify at-risk patients and provide early intervention. One example is the company’s early detection system, which securely captures and analyses various signifiers to alert practitioners of potentially critical health issues before they become serious.

MDClone has also been instrumental in developing new methods of collecting and managing patient data in areas such as electronic medical records (EMRs) and electronic health records (EHRs). By facilitating communication between healthcare providers, the platform allows them to exchange information from one system to another, improving accuracy in medical decisions. The technology’s potential doesn’t stop there: MDClone has shown great promise as a tool for increasing accuracy when it comes to diagnosis by incorporating artificial intelligence capabilities into its platform.

Overall, MDClone has made tremendous strides within the healthcare industry by introducing groundbreaking tools that enable more efficient collecting and processing of patient data—which ultimately leads to better quality care and improved outcomes for patients worldwide.

MDClone’s Series C Funding

Good news for healthcare technology company MDClone as it has announced the successful completion of its Series C Funding round, having raised a total of $63 million to fuel its global growth. This news comes when the healthcare industry increasingly relies on technology to optimise operations and efficiency.

Let’s take a closer look at MDClone’s Series C funding and what it could mean for the healthcare landscape.

Overview of Series C Funding

MDClone has secured Series C funding of $35 million, bringing its total funding to $77 million. This is a major milestone for MDClone, demonstrating the growing trust of investors in the company’s capabilities and mission and providing essential capital to accelerate the company’s growth.

The funds will fuel MDClone as it builds out its proprietary data platform to enable caregivers and organisations to manage vast complex healthcare data – providing unprecedented insights into patient populations. By leveraging advanced algorithms and machine learning, MDClone can create patient digital profiles that provide much-needed visibility into clinical improvement, performance optimization and risk assessment opportunities. The availability of MDClone’s data enrichment capabilities positions healthcare teams for improved workflow operations, enhanced financial outcomes and better quality of care for patients at a lower cost.

Series C funding was provided by a diverse group of global investors including Jerusalem Venture Partners (JVP), Tenaya Capital, Vertex Ventures US & HC, 8VC LLC, OurCrowd Qure – the healthcare technology fund of OurCrowd Equity Crowdfunding platform – and Moore Impact Fund through its Catalyst Initiative at Stanford University’s Graduate School of Business. Furthermore, Founders & Strategic Investors have contributed alongside existing venture investors including Vertex Ventures Israel (VVI), Full Cycle/Rhythm Capital Management LLC – and Elron Electronic Industries Ltd., forming an impressive portfolio of notable financial backers.

This announcement marks an important chapter in MDClone’s story – signalling both trust from existing investors in their capabilities and attracting new partners interested in democratising access to clinical intelligence that can improve patient outcomes with fewer resources.

Impact of Series C Funding on MDClone’s Global Expansion

MDClone, the leading cloud-based intelligence platform that anonymously extracts real-time patient data and AI algorithms to improve treatment outcomes, recently raised $42 million in a Series C venture capital round. This funding marks a major milestone for MDClone’s global expansion, allowing them to increase their reach and provide broad access to revolutionary healthcare tech and insightful analytics.

This influx of resources will enable MDClone to further advance its product platform while focusing on modernising healthcare systems worldwide. Along with expanding into new markets, these funds will also be used for implementing innovative research initiatives to align hospitals and medical centres with current industry benchmarks and deliver higher-quality care.

The results of MDClone’s Series C funding thus far have been overwhelmingly positive, with numerous healthcare providers eager to adopt the company’s expansive range of products. In addition, early adopters have reported reduced administrative burden – resulting in greater overall operational efficiency – and improved patient outcomes due to optimised medical decision processes enabled by the software’s advanced technologies.

Thanks in no small part to this new venture capital infusion, MDClone is poised for massive growth over the next several years. With its global impact on health IT already evident and expected future benefits around the corner, it’s easy to see why this company is quickly establishing itself as an essential partner in today’s digital healthcare landscape.

MDClone’s Global Expansion

MDClone, a healthcare technology company, recently raised $63 million in series C funding to fuel its global expansion. The company has seen tremendous growth since its founding in 2014, and this new capital will aid in its efforts to improve the lives of people around the world.

Let’s look closely at how MDClone is shaking up the healthcare landscape.

MDClone’s Expansion into Europe

MDClone Inc. is committed to expanding its Artificial Intelligence (AI)-driven precision medicine platform globally, and Europe has become an integral part of their global strategy. By targeting specific countries in the region and the entire European market, MDClone is transforming healthcare through comprehensive medical data solutions.

MDClone has recently established several offices throughout Europe to better serve the needs of clients and partners throughout the region. In addition to offices in France, Germany, Spain, UK and Austria, MDClone is actively targeting additional regions including Scandinavia, Balkans, Baltic States and Eastern Europe as part of its ongoing expansion efforts.

MDClone’s AI-powered platform provides access to real-time medical data that can be used for predictive analytics in health care scenarios such as patient risk stratification and cost prediction. By providing secure and reliable solutions to some of today’s most complex health care challenges, MDClone’s technology streamlines clinical processes in hospitals across seven countries with customers comprising leading hospitals, government agencies and private enterprise within these markets.

With customers across Europe leveraging MDClone’s innovative solutions for integrated patient care teams, disease management programs and workflow optimization services have all improved substantially resulting in more efficient outcomes for patients across unique regional markets within Europe under regulation GDPR legislation implementing best standards for data privacy requirements.

MDClone’s global expansion into other key geographic markets shows no signs of slowing down anytime soon as there is a clear demand from hospital groups seeking technology-enabled solutions specifically tailored to suit their local needs, which will continue to fuel the company’s growth trajectory into 2021 and beyond.

MDClone’s Expansion into Asia

MDClone, the world’s leading healthcare data aggregation and analysis platform, is quickly becoming the go-to solution for many healthcare providers and organisations across the globe. MDClone is revolutionising how healthcare institutions make data-driven decisions with its innovative artificial intelligence and machine learning capabilities.

The platform recently expanded into Asia in a move to revolutionise health care delivery not only in Asia but around the world. With its launch came the promise of improved access to health care information, better patient outcomes, and greater patient cost savings.

The utilisation of MDClone in Asian countries provides users access to powerful technology tools that help efficiently analyse large volumes of patient data. This helps clinicians to better identify problems before interventions are needed and ensures more proactive rather than reactive approaches when managing care of patients. In addition, using predictive medical modelling combined with sentiment analysis helps predict how patients are likely to respond to potential treatments thereby improving personalised care while reducing costs associated with treatment protocols with off target results.

MDClone also allows medical professionals access to up-to-date global medical evidence resources while effectively leveraging existing infrastructure thereby eliminating barriers such as differing language or geographic assortments that would otherwise impede timely diagnosis and treatment plans for patients.

Through this deployment, MDClone has become a market leader providing improved health care outcomes across diverse communities throughout Asia, giving them access to reliable tools backed by advanced technology that promote improved patient outcomes at lower costs than ever seen in global healthcare scenarios from Asia Pacific region through Middle East regions.

tags = mdclone digital health company, $63 million Series C round of funding, provides clinicians and healthcare professionals, explore healthcare data independently, israeli mdclone 63m warburg viola growthbenmelehbloomberg, israeli mdclone pincus viola growthbenmelehbloomberg, israeli mdclone 63m warburg pincus growthbenmelehbloomberg, israeli mdclone 63m pincus viola growthbenmelehbloomberg, israeli mdclone warburg viola growthbenmelehbloomberg, mdclone 63m pincus growthbenmelehbloomberg, israeli mdclone 63m viola growthbenmelehbloomberg, israeli mdclone 63m growthbenmelehbloomberg, mdclone 63m warburg viola growthbenmelehbloomberg, mdclone warburg pincus growthbenmelehbloomberg, mdclone warburg viola growthbenmelehbloomberg